Evolent Health Inc (EVH) concluded trading on Thursday at a closing price of $8.68, with 7.46 million shares of worth about $64.71 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -72.55% during that period and on February 27, 2025 the price saw a loss of about -8.15%. Currently the company’s common shares owned by public are about 115.04M shares, out of which, 114.47M shares are available for trading.
Stock saw a price change of -18.95% in past 5 days and over the past one month there was a price change of -16.70%. Year-to-date (YTD), EVH shares are showing a performance of -22.84% which decreased to -74.11% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.40 but also hit the highest price of $35.00 during that period. The average intraday trading volume for Evolent Health Inc shares is 2.30 million. The stock is currently trading -13.82% below its 20-day simple moving average (SMA20), while that difference is down -18.55% for SMA50 and it goes to -55.89% lower than SMA200.
Evolent Health Inc (NYSE: EVH) currently have 115.04M outstanding shares and institutions hold larger chunk of about 107.18% of that.
The stock has a current market capitalization of $1.01B and its 3Y-monthly beta is at 1.49. It has posted earnings per share of -$0.81 in the same period. It has Quick Ratio of 0.85 while making debt-to-equity ratio of 0.90. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EVH, volatility over the week remained 8.19% while standing at 5.47% over the month.
Stock’s fiscal year EPS is expected to rise by 18.14% while it is estimated to increase by 29.52% in next year. EPS is likely to grow at an annualized rate of 32.90% for next 5-years, compared to annual growth of 25.98% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Needham on January 10, 2025 offering a Buy rating for the stock and assigned a target price of $15 to it. Coverage by BTIG Research stated Evolent Health Inc (EVH) stock as a Buy in their note to investors on December 03, 2024, suggesting a price target of $29 for the stock. On November 08, 2024, Stephens Downgrade their recommendations, while on October 11, 2024, KeyBanc Capital Markets Initiated their ratings for the stock with a price target of $35. Stock get a Buy rating from Truist on August 09, 2024.
